Cue Biopharma, Inc. reported its financial results for the third quarter of 2026 and provided an update on its clinical development programs. The company announced that it has initiated the first-in-human Phase 1 trial for its lead autoimmune candidate, CUE-401.
Regarding its lead asset, CUE-221, the company released positive topline results from its Phase 2 study in chronic spontaneous urticaria (CSU). The study demonstrated highly statistically significant dose-responsive clinical impact on the primary endpoint of complete hives resolution (HSS7=0). A post-hoc analysis indicated that the 4 mg/kg dose group achieved a significantly higher rate of complete hive resolution compared to XOLAIR (omalizumab). Additionally, the company noted that the FDA has cleared the Investigational New Drug (IND) application for CUE-221 in food allergy.
Financially, the company reported third quarter 2026 revenue of $0.1 million, a decrease from $2.1 million in the same period in 2025. This decline was attributed to less revenue recognized under its BI Collaboration and License Agreement. Research and development expenses for the quarter were $17.0 million, up from $4.8 million in the prior year, primarily due to increased clinical trial costs and non-cash stock-based compensation. General and administrative expenses totaled $29.8 million for the quarter, compared to $4.9 million in 2025, also driven by non-cash stock-based compensation.
The company reported a net loss of $50.0 million for the three months ended September 30, 2026, compared to a net loss of $7.4 million in the prior year. As of September 30, 2026, the company held $57.9 million in cash and cash equivalents.